NCT04896112 2023-06-18
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Lynk Pharmaceuticals Co., Ltd
Phase 1 Withdrawn
Lynk Pharmaceuticals Co., Ltd
Medigene AG
Novartis
Northwestern University